An update on treatment of FIP using antiviral drugs in 2025: growing experience but more to learn (2025)
The authors affirm that they are independent and have received no financial compensation or other incentives for the preparation of this document
By filling out this form, we will ensure you are always sent the most up-to-date copy when the authors make updates.
An update on treatment of FIP using antiviral drugs in 2025: growing experience but more to learn
By Sam Taylor BVetMed(Hons) CertSAM DipECVIM-CA MANZCS (Medicine of Cats) PGCert FHEA FRCVS Veterinary Consultant, International Cat Care, Lumbry Park Veterinary Specialists, UK
Séverine Tasker BSc (hons) BVSc (hons) PhD DSAM DipECVIM-CA FHEA FRCVS Professor in Feline Medicine, University of Bristol, UK
Emi Barker BSc (hons) BVSc (hons) PhD PGCertTLHP DipECVIM-CA FRCVS Clinical Lead in Infectious Disease, Langford Vets, University of Bristol, UK
Danièlle Gunn-Moore BSc (Hon), BVM&S, PhD, MANZCVS (Medicine of Cats), FHEA, FRSB, FRCVS Professor of Feline Medicine, The Royal (Dick) School of Veterinary Studies and The Roslin Institute, the University of Edinburgh, UK
Stephanie Sorrell BVetMed (Hons) MANZCVS (Medicine of Cats) DipECVIM-CA MRCVS Internal Medicine Specialist, IDEXX UK
Petra Cerna PhD, DACVIM (SAIM), Dipl. ECVIM-CA), MANZCVS (Medicine of Cats), CertAVP (SAM-F), MRCVS, AFHEA, AvdCertFB Colorado State University
Sally Coggins, BVSc (Hons I) MANZCVS (Medicine of Cats) PhD, Postdoctoral research fellow (Diseases and Treatment of Cats), Sydney School of Veterinary Science, Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney
